Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Heralds Year Of 'Good Momentum' For Consumer Health Business

This article was originally published in The Tan Sheet

Executive Summary

J&J says following a year of innovation, 2016 will be a year of growth for its consumer business on the return of more recalled OTC brands and strong positioning in consumers' emerging self-care trend. The firm reports consumer division sales in 2015 slipped 6.8%, with a 9.5% drag from foreign currency exchange.

You may also be interested in...



Medtech's High-Earners: 2016 Executive Payouts Boosted By Bonuses, Stock Awards

A Medtech Insight analysis of the highest-earning CEOs among the top medtech companies in last year's MTI 100 company league table shows that these individuals benefited mainly from stock and options holdings, as well as very generous incentive bonuses, bestowed upon them by their boards of directors. However, a couple of CEOs, including Zimmer Biomet's David Dvorak and Cardinal Health's George Barrett, who were rewarded fiscally for taking their companies to growth have had their leadership challenged since then.

J&J Consumer Products Business Steers Toward Acquisitions For Growth

Sales of Tylenol, Motrin and other analgesics increased more than 13% during the firm's latest quarter as total US OTC sales reached $389m. Sales of the Listerine line grew 7% to drive domestic oral care product sales up 8.2% to $159m.

J&J Consumer Products Business Steers Toward Acquisitions For Growth

Sales of Tylenol, Motrin and other analgesics increased more than 13% during the firm's latest quarter as total US OTC sales reached $389m. Sales of the Listerine line grew 7% to drive domestic oral care product sales up 8.2% to $159m.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS108143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel